How EFPIA Set The Bar On Drug Safety Reporting During COVID-19
Executive Summary
Early disruptions caused by the coronavirus pandemic prompted the European pharmaceutical industry body, EFPIA, to establish a principles-based framework to help ensure consistency in managing compliance with pharmacovigilance responsibilities.
You may also be interested in...
EU Allows Pharma To Temporarily Prioritize Reporting For COVID-19 Adverse Events
Drug companies unable to continue with standard reporting of suspected adverse reactions to the EU pharmacovigilance database can temporarily prioritize their reporting activities to focus on COVID-19 related safety events.
Coronavirus Actions: How Pharma In India Is Handling Safety, Business Continuity
Scrip contacted a cross section of pharma firms in India to get a sense of how they are handling the extraordinary work-operations-employee well-being situation amid the coronavirus outbreak. Work from home mandates, deploying digital tools wherever possible, cut-back in field activities and daily temperature checks at sites are some of the initiatives set in motion.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.